Tilikum Therapeutics Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 1

Tilikum Therapeutics General Information

Description

Developer of inhibitors PARP-1 designed to cure patients with ovarian, breast, and prostate cancers. The company's anti-cancer drug attacks cancer cells in a smaller number of doses, enabling cancer patients to reduce the drug dosage intervals.

Contact Information

Website
tilikumtx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 6 Liberty Square
  • Boston, MA 02109-5800
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 6 Liberty Square
  • Boston, MA 02109-5800
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tilikum Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 01-Jun-2023 Completed Startup
To view Tilikum Therapeutics’s complete valuation and funding history, request access »

Tilikum Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Delin Ventures Venture Capital Minority
To view Tilikum Therapeutics’s complete investors history, request access »

Tilikum Therapeutics FAQs

  • When was Tilikum Therapeutics founded?

    Tilikum Therapeutics was founded in 2022.

  • Where is Tilikum Therapeutics headquartered?

    Tilikum Therapeutics is headquartered in Boston, MA.

  • What industry is Tilikum Therapeutics in?

    Tilikum Therapeutics’s primary industry is Drug Discovery.

  • Is Tilikum Therapeutics a private or public company?

    Tilikum Therapeutics is a Private company.

  • What is Tilikum Therapeutics’s current revenue?

    The current revenue for Tilikum Therapeutics is .

  • Who are Tilikum Therapeutics’s investors?

    Delin Ventures has invested in Tilikum Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process